Tourmaline Bio presents data from ongoing Phase 2 TRANQUILITY trial

Tourmaline Bio (TRML) presented additional data from its ongoing Phase 2 TRANQUILITY trial of pacibekitug in a poster presentation at the European Society of Cardiology Congress 2025 in Madrid, Spain, highlighting the consistency of reduction in high-sensitivity C-reactive protein with pacibekitug across a wide range of subgroups as well as concordant reductions in key biomarkers beyond hs-CRP, including lipoprotein(a), fibrinogen, and serum amyloid A. “Based on these results, pacibekitug became the first and only IL-6 inhibitor known to demonstrate deep hs-CRP reductions with quarterly dosing in a clinical trial, achieving greater than85% hs-CRP reductions from baseline in the 50 mg quarterly arm. These results support Tourmaline’s plans to initiate a Phase 2 proof-of-concept study in abdominal aortic aneurysm and to continue its preparations for a Phase 3 cardiovascular outcomes trial in patients with atherosclerotic cardiovascular disease,” the company stated.